LB Partners LLC Sells 82,947 Shares of Liquidia Co. (NASDAQ:LQDA)

LB Partners LLC cut its position in shares of Liquidia Co. (NASDAQ:LQDA) by 29.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 200,000 shares of the company’s stock after selling 82,947 shares during the period. Liquidia makes up 1.7% of LB Partners LLC’s portfolio, making the stock its 14th largest holding. LB Partners LLC owned about 0.26% of Liquidia worth $2,000,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Principal Financial Group Inc. grew its stake in Liquidia by 112.3% in the first quarter. Principal Financial Group Inc. now owns 36,462 shares of the company’s stock worth $538,000 after purchasing an additional 19,288 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Liquidia by 119.4% during the first quarter. BNP Paribas Financial Markets now owns 230,248 shares of the company’s stock valued at $3,396,000 after acquiring an additional 125,315 shares in the last quarter. Catalina Capital Group LLC increased its position in shares of Liquidia by 101.8% in the 1st quarter. Catalina Capital Group LLC now owns 21,416 shares of the company’s stock valued at $316,000 after acquiring an additional 10,801 shares during the period. Swiss National Bank purchased a new position in shares of Liquidia in the first quarter worth about $1,325,000. Finally, Sei Investments Co. acquired a new stake in Liquidia during the 1st quarter valued at approximately $531,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Stock Down 0.4 %

LQDA stock traded down $0.04 during midday trading on Monday, hitting $11.10. The company’s stock had a trading volume of 669,484 shares, compared to its average volume of 1,002,391. The firm has a market capitalization of $848.20 million, a P/E ratio of -7.04 and a beta of 0.22. The firm has a 50-day simple moving average of $10.41 and a 200-day simple moving average of $11.89. Liquidia Co. has a 52-week low of $6.04 and a 52-week high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $3.66 million during the quarter, compared to analysts’ expectations of $7.92 million. Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. On average, sell-side analysts expect that Liquidia Co. will post -1.69 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Caligan Partners Lp purchased 150,000 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were purchased at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the purchase, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Caligan Partners Lp acquired 150,000 shares of Liquidia stock in a transaction on Friday, August 30th. The stock was bought at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the purchase, the director now owns 6,994,997 shares in the company, valued at $66,522,421.47. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares of the company’s stock, valued at approximately $2,304,025.13. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,858 shares of company stock valued at $228,724. 31.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently weighed in on LQDA shares. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price target on shares of Liquidia in a research report on Monday, August 19th. BTIG Research dropped their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Monday, August 19th. Lifesci Capital started coverage on Liquidia in a research note on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price objective on the stock. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. Finally, Oppenheimer began coverage on Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $24.67.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).